← Back to patent-cliff list
CAS 2757103-57-2
(2alpha,5beta,7beta,13alpha)-1-Hydroxy-10-oxo-5,7,13-tris[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate
Codes：(XIII)101438-72-a,(XIII)101438-72-b
Application context (from source-drug indications)
乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(3aS,7S,9aS,10S,13S,13aS,13bS)-8-Hydroxy-13-(methoxymethoxy)-6,9a,14,14-tetramethyl-2-oxo-7,8,9,9a,10,11,12,13,13a,13b-decahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-10-yl benzoate→(3aS,7S,9aS,10S,13S,13aS,13bS)-8,13-Dihydroxy-6,9a,14,14-tetramethyl-2-oxo-7,8,9,9a,10,11,12,13,13a,13b-decahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-10-yl benzoate→(3aS,7S,9aS,10S,13aR,13bS)-6,9a,14,14-Tetramethyl-2,8,13-trioxo-7,8,9,9a,10,11,12,13,13a,13b-decahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-10-yl benzoate→(3aS,7S,9aS,10S,13aR,13bS)-10-Hydroxy-6,9a,14,14-tetramethyl-9a,10,11,12,13a,13b-hexahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8,13(7H,9H)-trione→(3aS,5S,9aS,10S,12R,13aR,13bS)-6,9a,14,14-Tetramethyl-5,10,12-tris[(triethylsilyl)oxy]-9a,10,11,12,13a,13b-hexahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8,13(5H,9H)-trione→(3aS,7S,9aS,10S,13aR,13bS)-6,9a,14,14-Tetramethyl-10-[(triethylsilyl)oxy]-9a,10,11,12,13a,13b-hexahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8,13(7H,9H)-trione→(3aS,7E,9aS,10S,13aR,13bS)-6,9a,14,14-Tetramethyl-8,10,13-tris[(triethylsilyl)oxy]-9,9a,10,11,13a,13b-hexahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxol-2-one→(3aS,3bR,4R,5R,7S,7aS,9Z,10aR,11aS,12aS)-7a,10a,13,13-Tetramethyl-4,7,9-tris[(triethylsilyl)oxy]-3b,4,5,6,7,7a,8,10a,11a,12-decahydro-2H,3aH-4,5-epoxy-10,12a-methanobenzo[3,4]oxireno[8,9]cyclodeca[1,2-d][1,3]dioxol-2-one→(3aS,5S,9aS,10S,12R,13aR,13bS)-5,12-Dihydroxy-6,9a,14,14-tetramethyl-10-[(triethylsilyl)oxy]-9a,10,11,12,13a,13b-hexahydro-2H,4H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8,13(5H,9H)-trione→(3aS,5S,9aS,10S,12R,13S,13aR,13bS)-13-Hydroxy-6,9a,13,14,14-pentamethyl-5,10,12-tris[(triethylsilyl)oxy]-4,5,9,9a,10,11,12,13,13a,13b-decahydro-2H,8H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8-dione→(3aS,5S,9aS,10S,12R,13aR,13bS)-6,9a,14,14-Tetramethyl-13-methylidene-5,10,12-tris[(triethylsilyl)oxy]-4,5,9,9a,10,11,12,13,13a,13b-decahydro-2H,8H-3a,7-methanobenzo[3,4]cyclodeca[1,2-d][1,3]dioxole-2,8-dione→Lithiumbenzene→(2alpha,5beta,7beta,13alpha)-1-Hydroxy-10-oxo-5,7,13-tris[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate
(2alpha,5beta,7beta,13alpha)-1-Hydroxy-10-oxo-5,7,13-tris[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate→(2alpha,5beta,7beta,13alpha)-1-Hydroxy-9-methyl-10-oxo-5,7,13-tris[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate→(2alpha,5alpha,7beta,10beta,13alpha)-10-(Acetyloxy)-5-bromo-1-hydroxy-9-oxo-7,13-bis[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-1,10-Dihydroxy-9-oxo-5,7,13-tris[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate→Acetic acid acetic anhydride→(2alpha,5beta,7beta,10beta,13alpha)-10-(Acetyloxy)-1-hydroxy-9-oxo-5,7,13-tris[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate→(2alpha,5beta,7beta,10beta,13alpha)-10-(Acetyloxy)-1,5-dihydroxy-9-oxo-7,13-bis[(triethylsilyl)oxy]taxa-4(20),11-dien-2-yl benzoate
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.